Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database.
Adenosquamous
Carcinoma
Gallbladder neoplasms
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
18
04
2020
accepted:
30
06
2020
pubmed:
25
7
2020
medline:
6
8
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
A paucity of data exists regarding adenosquamous carcinoma of the gallbladder, a histology comprising under 10% of gallbladder cancer diagnoses. The aim of this study is to characterize the clinicopathological features of these tumors utilizing a population-based dataset compared with gallbladder adenocarcinoma. We identified patients with gallbladder adenosquamous and adenocarcinoma from the National Cancer Database from 2004 to 2015. Patient demographics, tumor characteristics, treatment regimens, and overall survival were analyzed between the groups. We identified 13,158 patients: 12,455 (95%) with a diagnosis of gallbladder adenocarcinoma and 703 (5%) with adenosquamous carcinoma. Adenosquamous tumors were larger, poorly differentiated, and presented with Stage III/IV disease (75% vs 69%, p < 0.001). Overall 1-, 3-, and 5-year survival for adenosquamous and adenocarcinoma were 24%, 11%, and 9% vs 37%, 16%, and 11%, respectively (p < 0.001). Following surgical resection, adenosquamous carcinoma had more positive margins (31% vs 25%, p < 0.001), and median overall survival was 10.3 months vs 20.5 months for adenocarcinoma (p < 0.001). Overall survival at 1-, 3-, and 5-years for surgically resected adenosquamous and adenocarcinoma were 43%, 23%, and 18% versus 63%, 35%, and 25%, respectively (p < 0.001). In resected adenosquamous carcinoma, positive lymph nodes and margins were associated with worse survival, while adjuvant chemoradiation (HR 0.457, 95% CI 0.31-0.69, p < 0.001) was associated with improved survival. Adenosquamous gallbladder cancer presented with larger tumors at advanced clinical stages when compared with adenocarcinoma. Overall survival was worse for adenosquamous tumors both overall, and following curative intent resection. Adjuvant chemoradiation was associated with improved survival in adenosquamous tumors.
Sections du résumé
BACKGROUND
A paucity of data exists regarding adenosquamous carcinoma of the gallbladder, a histology comprising under 10% of gallbladder cancer diagnoses. The aim of this study is to characterize the clinicopathological features of these tumors utilizing a population-based dataset compared with gallbladder adenocarcinoma.
METHODS
We identified patients with gallbladder adenosquamous and adenocarcinoma from the National Cancer Database from 2004 to 2015. Patient demographics, tumor characteristics, treatment regimens, and overall survival were analyzed between the groups.
RESULTS
We identified 13,158 patients: 12,455 (95%) with a diagnosis of gallbladder adenocarcinoma and 703 (5%) with adenosquamous carcinoma. Adenosquamous tumors were larger, poorly differentiated, and presented with Stage III/IV disease (75% vs 69%, p < 0.001). Overall 1-, 3-, and 5-year survival for adenosquamous and adenocarcinoma were 24%, 11%, and 9% vs 37%, 16%, and 11%, respectively (p < 0.001). Following surgical resection, adenosquamous carcinoma had more positive margins (31% vs 25%, p < 0.001), and median overall survival was 10.3 months vs 20.5 months for adenocarcinoma (p < 0.001). Overall survival at 1-, 3-, and 5-years for surgically resected adenosquamous and adenocarcinoma were 43%, 23%, and 18% versus 63%, 35%, and 25%, respectively (p < 0.001). In resected adenosquamous carcinoma, positive lymph nodes and margins were associated with worse survival, while adjuvant chemoradiation (HR 0.457, 95% CI 0.31-0.69, p < 0.001) was associated with improved survival.
CONCLUSION
Adenosquamous gallbladder cancer presented with larger tumors at advanced clinical stages when compared with adenocarcinoma. Overall survival was worse for adenosquamous tumors both overall, and following curative intent resection. Adjuvant chemoradiation was associated with improved survival in adenosquamous tumors.
Identifiants
pubmed: 32705618
doi: 10.1007/s11605-020-04729-w
pii: 10.1007/s11605-020-04729-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1815-1827Informations de copyright
© 2020. The Society for Surgery of the Alimentary Tract.
Références
Lai CH, Lau WY. Gallbladder cancer--a comprehensive review. Surgeon. 2008;6(2):101-10.
pubmed: 18488776
doi: 10.1016/S1479-666X(08)80073-X
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
pubmed: 31912902
doi: 10.3322/caac.21590
Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11(5):671-81.
pubmed: 17468929
doi: 10.1007/s11605-006-0075-x
Horio T, Ogata S, Sugiura Y, Aiko S, Kanai N, Matsunaga H, et al. Cholecystic adenosquamous carcinoma mimicking Mirizzi syndrome. Can J Surg. 2009;52(3):E71-2.
pubmed: 19503654
pmcid: 2689754
Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M. Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res. 1994;85(4):389-99.
pubmed: 7911122
pmcid: 5919463
doi: 10.1111/j.1349-7006.1994.tb02372.x
Nishihara K, Takashima M, Furuta T, Haraguchi M, Tsuneyoshi M. Adenosquamous carcinoma of the gall-bladder with gastric foveolar-type epithelium. Pathol Int. 1995;45(3):250-6.
pubmed: 7787997
doi: 10.1111/j.1440-1827.1995.tb03450.x
Noske A, Pahl S. Combined adenosquamous and large-cell neuroendocrine carcinoma of the gallbladder. Virchows Arch. 2006;449(1):135-6.
pubmed: 16570181
doi: 10.1007/s00428-006-0171-z
Oohashi Y, Shirai Y, Wakai T, Nagakura S, Watanabe H, Hatakeyama K. Adenosquamous carcinoma of the gallbladder warrants resection only if curative resection is feasible. Cancer. 2002;94(11):3000-5.
pubmed: 12115390
doi: 10.1002/cncr.10578
Wagreich JM, Shapiro RS, Glajchen N, Seijo L. MRI findings in adenosquamous carcinoma of the gallbladder. Clin Imaging. 1998;22(2):130-3.
pubmed: 9543592
doi: 10.1016/S0899-7071(97)00079-X
Li D, Yang Z, Liu Z, Zou Q, Yuan Y. DDR2 and IFITM1 Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas. Pathol Oncol Res. 2019;25(1):157-67.
pubmed: 29043607
doi: 10.1007/s12253-017-0314-3
Li J, Yang ZL, Ren X, Zou Q, Yuan Y, Liang L, et al. ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol. 2013;34(1):359-68.
pubmed: 23065574
doi: 10.1007/s13277-012-0557-2
Li J, Yang ZL, Zou Q, Yuan Y, Li J, Liang L, et al. Squamous cell/adenosquamous carcinomas and adenocarcinomas of the gallbladder: an immunohistochemistry study of prognostic markers. Pathol Oncol Res. 2014;20(2):285-92.
pubmed: 24078426
doi: 10.1007/s12253-013-9693-2
Liu L, Yang ZL, Wang C, Miao X, Liu Z, Li D, et al. The Expression of Notch 1 and Notch 3 in Gallbladder Cancer and Their Clinicopathological Significance. Pathol Oncol Res. 2016;22(3):483-92.
pubmed: 26634853
doi: 10.1007/s12253-015-0019-4
Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J, et al. Paxillin and carbonic anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas. Histopathology. 2014;64(7):921-34.
pubmed: 24354963
doi: 10.1111/his.12341
Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J, et al. MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder. Mol Med Rep. 2016;14(5):4581-92.
pubmed: 27748889
pmcid: 5102005
doi: 10.3892/mmr.2016.5851
Luo Y, Yang ZL, Wang C, Miao X, Liu Z, Li D, et al. The clinicopathological significance of Jagged1 and DLL4 in gallbladder cancer. Tumori. 2017;103(6):557-65.
pubmed: 27174628
doi: 10.5301/tj.5000519
Wu ZC, Xiong L, Wang LX, Miao XY, Liu ZR, Li DQ, et al. Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder. World J Gastroenterol. 2017;23(14):2601-12.
pubmed: 28465645
pmcid: 5394524
doi: 10.3748/wjg.v23.i14.2601
Yang Z, Yang Z, Zou Q, Yuan Y, Li J, Li D, et al. A comparative study of clinicopathological significance, FGFBP1, and WISP-2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder. Int J Clin Oncol. 2014;19(2):325-35.
pubmed: 23592278
doi: 10.1007/s10147-013-0550-9
Yang ZL, Miao X, Xiong L, Zou Q, Yuan Y, Li J, et al. CFL1 and Arp3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinomas of gallbladder. Cancer Invest. 2013;31(2):132-9.
pubmed: 23320827
doi: 10.3109/07357907.2012.756113
Yuan Y, Yang ZL, Miao XY, Liu ZR, Li DQ, Zou Q, et al. EphB1 and Ephrin-B, new potential biomarkers for squamous cell/adenosquamous carcinomas and adenocarcinomas of the gallbladder. Asian Pac J Cancer Prev. 2014;15(3):1441-6.
pubmed: 24606480
doi: 10.7314/APJCP.2014.15.3.1441
Zou Q, Yang ZL, Yuan Y, Li JH, Liang LF, Zeng GX, et al. Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma. World J Surg Oncol. 2013;11:143.
pubmed: 23782473
pmcid: 3691597
doi: 10.1186/1477-7819-11-143
Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24(8):1069-78.
pubmed: 21532545
doi: 10.1038/modpathol.2011.68
Kim WS, Jang KT, Choi DW, Choi SH, Heo JS, You DD, et al. Clinicopathologic analysis of adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol. 2011;103(3):239-42.
pubmed: 21337551
doi: 10.1002/jso.21813
Song HW, Chen C, Shen HX, Ma L, Zhao YL, Zhang GJ, et al. Squamous/adenosquamous carcinoma of the gallbladder: Analysis of 34 cases and comparison of clinicopathologic features and surgical outcomes with adenocarcinoma. J Surg Oncol. 2015;112(6):677-80.
pubmed: 26458491
doi: 10.1002/jso.24065
Akce M, Zakka K, Penley M, Jiang R, Alese OB, Shaib WL, et al. Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. J Surg Oncol. 2019.
Samuel S, Mukherjee S, Ammannagari N, Pokuri VK, Kuvshinoff B, Groman A, et al. Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. PLoS One. 2018;13(6):e0198809.
pubmed: 29889907
pmcid: 5995371
doi: 10.1371/journal.pone.0198809
Chan KM, Yu MC, Lee WC, Jan YY, Chen MF. Adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol. 2007;95(2):129-34.
pubmed: 17262729
doi: 10.1002/jso.20576
Charbit A, Malaise EP, Tubiana M. Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer. 1971;7(4):307-15.
pubmed: 4328281
doi: 10.1016/0014-2964(71)90073-9
Surgeons ACo. American College of Surgeons: National Cancer Database. [Available from: https://www-facs-org.foyer.swmed.edu/quality-programs/cancer/ncdb .
Fritz AG. International classification of diseases for oncology : ICD-O. 3rd ed. Geneva: World Health Organization; 2000. vii, 240 p. p.
Dong F, Lu C, Chen X, Guo Y, Liu J. CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. Diagn Pathol. 2015;10:137.
pubmed: 26249215
pmcid: 4545819
doi: 10.1186/s13000-015-0375-0
Enyu L, Na W, Chuanzong Z, Ben W, Xiaojuan W, Yan W, et al. The clinical significance and underlying correlation of pStat-3 and integrin alphavbeta6 expression in gallbladder cancer. Oncotarget. 2017;8(12):19467-77.
pubmed: 28061445
pmcid: 5386698
doi: 10.18632/oncotarget.14444
Galuppini F, Salmaso R, Valentini E, Lanza C, Maretto I, Nitti D, et al. Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components. Pathol Res Pract. 2017;213(8):1010-3.
pubmed: 28698100
doi: 10.1016/j.prp.2017.05.004
Narayan RR, Creasy JM, Goldman DA, Gonen M, Kandoth C, Kundra R, et al. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. Cancer. 2019;125(4):575-85.
pubmed: 30427539
doi: 10.1002/cncr.31850
Yuan Y, Yang ZL, Zou Q, Li JH, Li DQ, Liang LF, et al. Comparative study of clinicopathological significance, BIRC7, and STC2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Neoplasma. 2013;60(6):698-705.
pubmed: 23906305
doi: 10.4149/neo_2013_089
Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019;37(8):658-67.
pubmed: 30707660
doi: 10.1200/JCO.18.00050
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663-73.
pubmed: 30922733
doi: 10.1016/S1470-2045(18)30915-X
Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-8.
pubmed: 26254683
doi: 10.1016/S1470-2045(15)00040-6
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215-23.
pubmed: 16983741
doi: 10.1002/bjs.5506
Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644-50.
pubmed: 16110023
doi: 10.1200/JCO.2005.08.144
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827-33.
pubmed: 23008301
doi: 10.1200/JCO.2012.42.9597
van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82.
pubmed: 21596621
doi: 10.1016/S1470-2045(11)70097-3
Hoshimoto S, Hoshi S, Hishinuma S, Tomikawa M, Shirakawa H, Ozawa I, et al. Adenosquamous carcinoma in the biliary tract: association of the proliferative ability of the squamous component with its proportion and tumor progression. Scand J Gastroenterol. 2017;52(4):425-30.
pubmed: 28034323
doi: 10.1080/00365521.2016.1273383
Mori M, Iwashita A, Enjoji M. Squamous cell carcinoma of the stomach: report of three cases. Am J Gastroenterol. 1986;81(5):339-42.
pubmed: 3706247
Hanada M, Shimizu H, Takami M. Squamous cell carcinoma of the gallbladder associated with squamous metaplasia and adenocarcinoma in situ of the mucosal columnar epithelium. Acta Pathol Jpn. 1986;36(12):1879-86.
pubmed: 3825536
Karasawa T, Itoh K, Komukai M, Ozawa U, Sakurai I, Shikata T. Squamous cell carcinoma of gallbladder--report of two cases and review of literature. Acta Pathol Jpn. 1981;31(2):299-308.
pubmed: 7257770
Yan HX, Li QL, Cai WW, Tang D, Wang B, Liu X, et al. EphA10 and EphB3 are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas. Int J Clin Exp Pathol. 2018;11(2):512-25.
pubmed: 31938137
pmcid: 6958000